Long-term data on Dendreons Mylovenge vaccine presented at American Society of Hematology Meeting
Results of Phase II studies indicate disease stabilization in patients with multiple myeloma, amyloidosis
San Francisco, CA (Dec. 2, 2000) Dendreon Corporation today announced that long-term follow-up data from Phase II trials of its therapeutic vaccine Mylovenge were presented at the American Society of Hematology Annual Meeting in San Francisco. The trials, involving patients with multiple myeloma and with amyloidosis, indicate that Mylovenge causes regression or stabilization in more than 30 percent of patients. In some patients, these benefits were found to extend more than 18 months following treatment.
Data were presented Saturday at the American Society of Hematology Annual Meeting in San Francisco by Dr. Martha Lacy of the Mayo Clinic, principal investigator of studies involving multiple myeloma and amyloidosis patients by and Dr. Malcolm MacKenzie, director of the Sacramento Medical Foundation Blood Center and principal investigator of a multi-center trial involving further patients with multiple myeloma.
In MacKenzies multicenter trial, approximately 40 percent of the 42 multiple myeloma patients evaluated have shown benefits either in terms of disease stabilization or in tumor regression. This includes six patients with decreases in serum M protein and 10 patients with disease stabilization more than six months. Four patients have been stable for more than 18 months following treatment.
In the Mayo trial of multiple myeloma patients, 17 patients were treated with Mylovenge. Clinical responses were seen in five patients, including complete or near-complete regressions. Many of these responses continued for more than one year.
In a further Mayo trial, 10 patients with amyloidosis were treated with Mylovenge. Seven had disease stabilization or regression lasting in four cases for 18 mo
'"/>
Contact: Page Sargisson
p.sargisson@noonanrusso.com
415-677-4455 x 229
Noonan/Russo Communications
1-Dec-2000